Holen Sie sich die Stockscreener-App
7.39
1.51%
0.11
Handel nachbörslich:
7.40
0.01
+0.14%
Schlusskurs vom Vortag:
$7.28
Offen:
$7.28
24-Stunden-Volumen:
723.14K
Relative Volume:
0.57
Marktkapitalisierung:
$503.88M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-50.75M
KGV:
-9.8428
EPS:
-0.7508
Netto-Cashflow:
$-44.43M
1W Leistung:
+0.14%
1M Leistung:
+58.92%
6M Leistung:
+209.21%
1J Leistung:
+424.11%
1-Tages-Spanne:
$6.803
$7.455
1-Wochen-Bereich:
$6.5801
$7.59
52-Wochen-Spanne:
$1.05
$7.59
Climb Bio Inc Stock (CLYM) Company Profile
Firmenname
Climb Bio Inc
Sektor
Branche
Telefon
1-866-857-2596
Adresse
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
7.39 | 496.38M | 0 | -50.75M | -44.43M | -0.7508 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-16 | Eingeleitet | William Blair | Outperform |
| 2025-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-08-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-06-06 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Climb Bio Inc Aktie (CLYM) Neueste Nachrichten
Wedbush Begins Coverage on Climb Bio (NASDAQ:CLYM) - MarketBeat
Wedbush Initiates Climb Bio at Outperform With $12 Price Target - marketscreener.com
Wedbush initiates Climb Bio stock with Outperform rating - Investing.com
Climb 2025 10-K: $0 Revenue, $(0.88) EPS and $59.9M Net Loss - TradingView
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - The Manila Times
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Insider Sell Alert: Stephen Thomas Sells 50,000 Shares of Climb Bio Inc (CLYM) - GuruFocus
Climb Bio Highlights 2025 Data Catalysts, CD19 and APRIL Programs at Oppenheimer Conference - MarketBeat
Climb Bio (CLYM) Price Target Increased by 20.30% to 11.66 - Nasdaq
Proposed 50,000-share sale by CLYM broker (CLYM) - Stock Titan
CLYM: Multiple clinical readouts expected in 2024 for antibody therapies in PMN, ITP, and IgAN - TradingView
CLYM: Five clinical data readouts expected in 2024, with cash runway secured into 2028 - TradingView
Aug Update: What is Fresh Del Monte Produce Incs 5 year growth outlookJuly 2025 Setups & Verified Entry Point Detection - baoquankhu1.vn
CLYM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Climb Bio’s Stock Run Puts All Eyes On 2026 Trial Data - Finimize
Klein Hersh Recruits Chief Medical Officer for Zag Bio - Hunt Scanlon Media
Piper Sandler initiates coverage of Climb Bio (CLYM) with overweight recommendation - MSN
Surprises Report: Is Climb Bio Inc a stock for growth or value investorsPortfolio Performance Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Climb Bio (CLYM) director sells 100,000 shares in planned trades - Stock Titan
What’s the analyst consensus on Climb Bio Inc.Earnings Beat & Verified Short-Term Trading Plans - mfd.ru
This Taiwan Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Climb Bio Teases 5 Data Readouts in 2026, Highlights CD19 and APRIL “Sweeper” Programs at Summit - MarketBeat
Piper Sandler initiates Climb Bio stock with Overweight rating, $23 target - Investing.com Canada
CLYM: Five clinical readouts in 2024 and strong cash runway drive autoimmune pipeline progress - TradingView
CLYM (NASDAQ: CLYM) shareholder files to sell 100,000 shares - Stock Titan
Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation - Sahm
Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Climb Bio to Present at Upcoming Investor Conferences - The Manila Times
Top High Flyer Healthcare Stocks Revealed - Intellectia AI
Cheap high flyer healthcare stockshigh momentum and low valuation (CLYM:NASDAQ) - Seeking Alpha
Activity Recap: Can Barings BDC Inc weather a recessionPortfolio Update Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Day Trade: Can Climb Bio Inc sustain its profitabilityPortfolio Performance Report & Accurate Trade Setup Notifications - baoquankhu1.vn
Tech Rally: Will Vishay Precision Group Inc announce a stock split2025 Big Picture & Capital Protection Trade Alerts - baoquankhu1.vn
Aug Macro: Can Climb Bio Inc outperform in the next rallyLayoff News & Daily Chart Pattern Signals - baoquankhu1.vn
Zag Bio Appoints Jan Hillson, M.D., as Chief Medical Officer - Business Wire
Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate - Yahoo Finance
Ten new option listings and two option delistings on January 22nd - TipRanks
HubSpot, Inc. (HUBS) Stock Analysis: Can It Climb 86.84% To Meet Analysts' Targets? - directorstalkinterviews.com
Climb Bio, Inc. (NASDAQ:CLYM) Short Interest Update - MarketBeat
ImmunityBio shares climb as bladder cancer trial nears full enrollment, BLA submission expected by year end - Seeking Alpha
ImmunityBio shares climb 3% premarket after company's prelim quarterly revenue exceeds estimates - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Climb Bio (CLYM), Travere Therapeutics (TVTX) - The Globe and Mail
Resistance Check: How Climb Bio Inc stock benefits from tech adoption2025 Bull vs Bear & Long-Term Growth Portfolio Plans - Bộ Nội Vụ
Patterns Watch: How Climb Bio Inc stock benefits from tech adoption2025 Trading Volume Trends & Weekly Hot Stock Watchlists - Bộ Nội Vụ
Winners Losers: Is Climb Bio Inc stock positioned well for digital economyJuly 2025 PostEarnings & Daily Profit Maximizing Trade Tips - Bộ Nội Vụ
Bull Bear: Is Climb Bio Inc stock positioned well for digital economyJuly 2025 Chart Watch & High Conviction Buy Zone Picks - Bộ Nội Vụ
Laser Focus WorldClimb Bio to Present at Upcoming September 2025 Investor Conferences - FinancialContent
Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Update Report: Why analysts upgrade Climb Bio Inc stockJuly 2025 Review & Real-Time Buy Signal Notifications - moha.gov.vn
Can Climb Bio Inc. stock deliver sustainable ROEMarket Trend Review & Weekly Top Gainers Trade List - ulpravda.ru
Finanzdaten der Climb Bio Inc-Aktie (CLYM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Climb Bio Inc-Aktie (CLYM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thomas Stephen Basil | Director |
Feb 26 '26 |
Sale |
7.01 |
16,313 |
114,289 |
154,657 |
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):